🧪 Why This Could be the Top Biotech Stock to Watch in 2023

The tech visionary who built a $1.6 trillion company from scratch has backed a tiny biotech with a new way to treat Alzheimer's. [The Smart Dividend Main logo]( [Unsubscribe]( A note from the Editor: The Smart Dividend is dedicated to providing readers like you with unique opportunities. The message below from one of our business associates is one we believe you should take a serious look at. [divider] Hello Fellow Investor! [Back in December, an ex-Wall Street CEO made a bold prediction about the biotech sector…]( He stated that “M & A activity will start accelerating soon.” It seemed unlikely at the time… But the next day, Pfizer bought Arena Pharmaceuticals…and shares jumped up 83% in a single day. Then, just 9 days later, Novartis bought Gyroscope Therapeutics in a $1.6 billion deal. His prediction doesn’t seem so unlikely anymore. [Click here to find out which biotech firm I predict will get taken over next…and how it could unlock huge profits for forward-thinking investors.]( "The Buck Stops Here" Dylan Jovine, CEO and Founder, Behind the Markets [footer divider] We select the best news from our partners by analyzing both the interest of our readers and relevance of the content. You can leave your feedback by reaching us here - support@thesmartdividend.com This ad is sent on behalf of Behind The Markets, 4260 NW 1st Avenue, Suite # 55 Boca Raton, FL 33431 – 4264. If you would like to unsubscribe from receiving offers from Behind The Markets, please [click here](. It’s a good idea to [whitelist us]( to make sure you get every email. 25 N River Ln, Geneva, IL 60134, United States © 2023 The Smart Dividend. All Rights Reserved. [Privacy Policy]( | [Terms & Conditions]( | [Unsubscribe]( [footer logo](